

DEPARTMENT OF HEALTH AND HUMAN SERVICES
WASHINGTON, D.C.

ESTABLISHMENT LICENSE

FOR THE MANUFACTURE OF
BIOLOGICAL PRODUCTS

This is to certify that Establishment License No. 602 is hereby issued
to Central Jersey Blood Center, the manufacturer,
located at Shrewsbury, New Jersey, through the establishment
identified as Central Jersey Blood Center,
located at Shrewsbury, New Jersey.

pursuant to Section 351 of the Public Health Service Act, approved July 1, 1944 (58 Stat. 702, 42 U.S.C. 262), as amended, and the regulations thereunder. The license authorizes the manufacturer to maintain an establishment for the propagation or manufacture and preparation for sale, barter, or exchange in the District of Columbia, or for sending, carrying, or bringing for sale, barter, or exchange from any State or possession into any other State or possession or into any foreign country, or from any foreign country into any State or possession, any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, or arsphenamine or its derivatives, for which the manufacturer holds an unsuspended and unrevoked product license issued by the Secretary of Health and Human Services pursuant to said Act and regulations.

Date 8/24/93



Mary Sue Layton
for Director, Center for Biologics
Evaluation and Research
Food and Drug Administration